Could a new pill ease borderline personality disorder?
NCT ID NCT05356013
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This study tested whether Caplyta (lumateperone) can reduce symptoms of borderline personality disorder (BPD) in adults. Sixty people with BPD received either Caplyta or a placebo for 8 weeks. The goal was to see if Caplyta leads to greater improvement in BPD symptoms compared to placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE PERSONALITY DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.